Cipher Pharmaceuticals Inc (CPH):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cipher Pharmaceuticals Inc (CPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3421
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cipher Pharmaceuticals Inc (Cipher) is a pharmaceutical company that develops skin care solutions. The company provides products such as actikerall, a topical solution indicated for the treatment of hyperkeratotic actinic keratosis; beteflam, a topical patch used for the treatment of mild to moderate plaque psoriasis of the elbows and knee in adults; epuris, an oral retinoid indicated for the treatment of severe nodular and inflammatory acne; and vaniqa, a topical cream indicated to reduce the growth of unwanted facial hair in women. Its pipeline products under development can be used in the treatment of seborrheic dermatitis, plaque psoriasis, chronic pruritus, rheumatoid arthritis, late stage melanoma, and others. Cipher’s pre-clinical compounds are intended for the treatment of melanoma and other cancers. The company provides healthcare professionals with several non-prescription products. Cipher is headquartered in Mississauga, Ontario, Canada.

Cipher Pharmaceuticals Inc (CPH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cipher Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Cipher Pharma Acquires Canadian Rights to Vaniqa and Actikerall from Almirall 13
Cipher Pharma Acquires Rights to Dermadexin, Pruridexin and ASF-1096 from Astion Pharma 14
Partnerships 15
Cipher Pharma and Italmex Enter into Distribution Agreement 15
Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 16
Cipher Pharma Enters Into Distribution Agreement With Tecnofarma For CIP-Tramadol ER 17
Licensing Agreements 18
Cipher Pharma Enters into Licensing Agreement with Aclaris Therapeutics 18
Cipher Pharma Enters into Licensing Agreement with Synergy Pharma 19
Cipher Pharma Enters into Licensing Agreement with Pennsylvania State University 20
Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 21
Cipher Pharma Enters into Licensing Agreement with Ferrer for Ozenoxacin 22
BioAlliance Pharma Enters Into Licensing Agreement With Innocutis For Sitavig 23
Melanovus Oncology Enters into Licensing Agreement with Penn State Research Foundation 24
Cipher Pharma Enters Into Licensing Agreement With IBSA Institut Biochimique For Betesil Patch 25
Edesa Biotech Enters into Licensing Agreement with Cipher Pharma 26
Debt Offering 27
Cipher Pharma Raises USD100 Million in a Private Placement of 10.25% Notes Due 2020 27
Asset Transactions 28
EPI Health Acquires US Commercial Assets from Cipher Pharma 28
Acquisition 29
Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 29
Cipher Pharma Acquires Innocutis 31
Cipher Pharmaceuticals Inc – Key Competitors 32
Cipher Pharmaceuticals Inc – Key Employees 33
Cipher Pharmaceuticals Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Aug 10, 2018: Cipher Pharmaceuticals reports Q2 2018 results 35
May 10, 2018: Cipher Pharmaceuticals Reports Q1 2018 Results 37
Feb 28, 2018: Cipher Pharmaceuticals Reports Q4 & FY2017 Results 39
Nov 03, 2017: Cipher Pharmaceuticals Reports Q3 2017 Operating & Financial Results 41
Aug 11, 2017: Cipher Pharmaceuticals reports Q2 2017 financial results 43
Mar 02, 2017: Cipher Pharmaceuticals Reports 2016 Q4 & Year-End Financial Results 44
Corporate Communications 45
Apr 12, 2017: Cipher Pharmaceuticals Proposes Adding Robert Tessarolo and Arthur Deboeck to Board of Directors 45
Mar 20, 2017: Cipher Pharmaceuticals Appoints Robert D. Tessarolo as CEO 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cipher Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cipher Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cipher Pharma Acquires Canadian Rights to Vaniqa and Actikerall from Almirall 13
Cipher Pharma Acquires Rights to Dermadexin, Pruridexin and ASF-1096 from Astion Pharma 14
Cipher Pharma and Italmex Enter into Distribution Agreement 15
Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 16
Cipher Pharma Enters Into Distribution Agreement With Tecnofarma For CIP-Tramadol ER 17
Cipher Pharma Enters into Licensing Agreement with Aclaris Therapeutics 18
Cipher Pharma Enters into Licensing Agreement with Synergy Pharma 19
Cipher Pharma Enters into Licensing Agreement with Pennsylvania State University 20
Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 21
Cipher Pharma Enters into Licensing Agreement with Ferrer for Ozenoxacin 22
BioAlliance Pharma Enters Into Licensing Agreement With Innocutis For Sitavig 23
Melanovus Oncology Enters into Licensing Agreement with Penn State Research Foundation 24
Cipher Pharma Enters Into Licensing Agreement With IBSA Institut Biochimique For Betesil Patch 25
Edesa Biotech Enters into Licensing Agreement with Cipher Pharma 26
Cipher Pharma Raises USD100 Million in a Private Placement of 10.25% Notes Due 2020 27
EPI Health Acquires US Commercial Assets from Cipher Pharma 28
Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 29
Cipher Pharma Acquires Innocutis 31
Cipher Pharmaceuticals Inc, Key Competitors 32
Cipher Pharmaceuticals Inc, Key Employees 33
Cipher Pharmaceuticals Inc, Subsidiaries 34

List of Figures
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cipher Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cipher Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Cipher Pharmaceuticals Inc (CPH):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Givaudan SA:戦略・SWOT・企業財務分析
    Givaudan SA - Strategy, SWOT and Corporate Finance Report Summary Givaudan SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Biocon Ltd (BIOCON):製薬・医療:M&Aディール及び事業提携情報
    Summary Biocon Ltd (Biocon) is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions like cancer, diabetes and autoimmune. The company produces a wide range of active pharmaceutical ingredients (APIs), branded formulations; and …
  • Albireo Pharma Inc (ALBO):企業の財務・戦略的SWOT分析
    Albireo Pharma Inc (ALBO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Eisai Inc-製薬・医療分野:企業M&A・提携分析
    Summary Eisai Inc (Eisai) is a healthcare company, which focuses on the discovery, development and marketing of pharmaceutical products. The company's major products include Aricept for Alzheimer’s treatment, Aciphex for acid reflux, Akynzeo for nausea and vomiting dring the course of cancer chemoth …
  • Tuas Power Ltd:企業の戦略的SWOT分析
    Tuas Power Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • DCP Midstream, LP:企業の戦略・SWOT・財務分析
    DCP Midstream, LP - Strategy, SWOT and Corporate Finance Report Summary DCP Midstream, LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Manila Electric Co (MER):電力:M&Aディール及び事業提携情報
    Summary Manila Electric Co (MERALCO) is an electric distribution utility company. It constructs, operates and maintains the electricity distribution system in the cities and municipalities of Bulacan, Metro Manila, Cavite, and Rizal and certain cities, municipalities, and barangays in the provinces …
  • Church & Dwight Co Inc:企業のM&A・事業提携・投資動向
    Church & Dwight Co Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Church & Dwight Co Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Price Forbes & Partners Ltd.:企業の戦略・SWOT・財務情報
    Price Forbes & Partners Ltd. - Strategy, SWOT and Corporate Finance Report Summary Price Forbes & Partners Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Bank Rossiya:企業の戦略・SWOT・財務分析
    Bank Rossiya - Strategy, SWOT and Corporate Finance Report Summary Bank Rossiya - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Contact Energy Ltd (CEN):電力:M&Aディール及び事業提携情報
    Summary Contact Energy Ltd (Contact Energy) is an energy company that generates electricity and sells electricity, natural gas and liquefied petroleum gas to customers. It generates electricity from various sources of energy including thermal, hydro and geothermal sources of energy. It supplies elec …
  • Aksigorta A.S. (AKGRT):企業の財務・戦略的SWOT分析
    Aksigorta A.S. (AKGRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Biovista Inc-製薬・医療分野:企業M&A・提携分析
    Summary Biovista Inc (Biovista) is a drug development company that provides COSS platform technology support in uncovering non-obvious correlations between drugs. The company’s products are used for the treatment of neurodegenerative diseases, epilepsy, oncology and orphan diseases. It offers servic …
  • A. Menarini Industrie Farmaceutiche Riunite Srl:企業の戦略的SWOT分析
    A. Menarini Industrie Farmaceutiche Riunite Srl - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competito …
  • Trovagene Inc (TROV)-製薬・医療分野:企業M&A・提携分析
    Summary Trovagene Inc (Trovagene) is a development stage molecular diagnostic company focusing on the development and commercialization of proprietary molecular genetic detection technologies for screening and monitoring cancer and other diseases. Its product portfolio includes liquid biopsy tests t …
  • Bourbon Corp:企業の戦略・SWOT・財務分析
    Bourbon Corp - Strategy, SWOT and Corporate Finance Report Summary Bourbon Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Allscripts Healthcare Solutions Inc (MDRX):医療機器:M&Aディール及び事業提携情報
    Summary Allscripts Healthcare Solutions Inc (Allscripts), formerly Allscripts-Misys Healthcare Solutions, Inc., is a provider of healthcare information technology solutions. The company’s major solutions include Electronic Health Records (EHR), Financial Management Solutions, Population Health Manag …
  • Kalvista Pharmaceuticals Inc (KALV):医療機器:M&Aディール及び事業提携情報
    Summary Kalvista Pharmaceuticals Inc (Kalvista), formerly Carbylan Therapeutics Inc, is a pharmaceutical company that discovers, develops and commercializes small molecule protease inhibitors. The company’s product candidates are inhibitors of plasma kallikrein, which is being developed for heredita …
  • Chronos Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Chronos Therapeutics Ltd (Chronos) is a developer of medications for degenerative and behavioural diseases of the brain and nervous system. The company offers research and development, screening, discovery, repositioning and acquisition programs. Its pipeline products comprise RDC5 neurodege …
  • Ocean Rig UDW Inc (ORIG):企業の財務・戦略的SWOT分析
    Summary Ocean Rig UDW Inc (Ocean Rig), formerly Primelead Shareholders Inc is an offshore drilling contractor that offers oilfield services. The company owns and operates 13 offshore ultra deepwater drilling units including ultra deepwater semi submersible drilling rigs, and ultra deepwater drillshi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆